Open-Label Extension Study of Setmelanotide

Summary

This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromic, or acquired diseases of obesity upstream of the MC4R pathway.

Timeline

Start

2024-10-21

Primary completion

2026-06-24

Completion

2026-06-24

Drugs

Indications